Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 14/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.63 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL886422 | 0.87 | KCNA5 (0.64) | KCNA5KCNH2L3MBTL1MAPK1 | |
| SCHEMBL2063801 | 0.86 | KCNA5 (0.57) | KCNA5KCNH2PDK2MAPK1 | |
| SCHEMBL885139 | 0.85 | KCNA5 (0.55) | KCNA5KCNH2L3MBTL1JAK2MAPK1 | |
| SCHEMBL2063286 | 0.85 | KCNA5 (0.64) | KCNA5KCNH2PDK2L3MBTL1MAPK1 | |
| SCHEMBL2063186 | 0.83 | KCNA5 (0.69) | KCNA5KCNH2 | |
| SCHEMBL2062779 | 0.79 | KCNA5 (1.00) | KCNA5KCNH2MAPK1 | |
| SCHEMBL3623417 | 0.78 | PDK2 (0.42) | KCNA5KCNH2PDK2L3MBTL1JAK2 | |
| SCHEMBL2063707 | 0.77 | KCNA5 (1.00) | KCNA5KCNH2MAPK1 | |
| SCHEMBL2063325 | 0.76 | KCNA5 (1.00) | KCNA5KCNH2MAPK1 | |
| SCHEMBL1370072 | 0.75 | PDK2 (0.43) | KCNH2PDK2L3MBTL1JAK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | claimed |
| US-8148535-B2 | Potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | KCNA5 11/4885KCNH2 3/4885PDK2 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.